Choosing your SEP battleground: UPC, Germany or UK?

​
June 7, 2026

Litigation in Europe offers SEP owners a range of strategic options: the UK courts provide a leading forum for global FRAND rate-setting, while the German courts and the UPC offer powerful avenues for securing timely injunctive relief. This article distils the key points that SEP owners should have in mind when choosing between these jurisdictions.

Germany and UPC v UK - contrasting approaches to the FRAND defence

Germany and UPC

The FRAND defence in the German courts and the UPC arises under EU competition law and the “FRAND dance” set out in the CJEU’s Huawei v ZTE decision. The courts carry out a holistic, conduct-based assessment, rather than treating Huawei v ZTE as a rigid step by step checklist. Recent decisions from both systems confirm that the central question is whether the parties’ behaviour throughout the licensing negotiations evidences a genuine attempt to conclude a licence on FRAND terms. In almost all infringement decisions to date, the German courts have rejected the implementer’s FRAND defence and awarded the SEP owner an injunction, often without undertaking a detailed examination of whether the SEP owner’s offer is FRAND compliant. The UPC has adopted a similar approach, with four decisions from three German Local Divisions rejecting the FRAND defence and awarding injunctive relief.

UK

By contrast, the UK views FRAND primarily as a matter of contract law. Normally a patentee would be able to obtain a UK injunction against an infringer; however, if the patent is subject to a FRAND commitment, the implementer can rely upon that contractual commitment to avoid the injunction by compelling the patentee to offer a FRAND licence. As a result, the UK courts have in four cases so far determined what the terms, including royalties, are for the FRAND licence that the patentee is required to offer.

To demonstrate their willingness, SEP owners or implementers (and, in some UK FRAND cases, both) have given a binding undertaking to the UK courts to enter into the court-determined licence. However, if an implementer does not give that undertaking, and is found to infringe a valid UK SEP, the UK court will injunct them.

Choosing between German national and UPC proceedings

Territorial reach of the UPC

A defining feature of UPC litigation is its multi-territorial reach. In a single infringement action, the claimant may seek remedies, including injunctive relief, across multiple participating Member States in which the patent is in force. In FRAND disputes, a multi jurisdiction injunction arising from a single court proceeding can be a powerful tool against an implementer with a significant commercial presence in multiple UPC participant countries.

Timings

UPC proceedings are structured around tight timelines and a front-loaded written phase. Aimed at reaching an oral hearing on the merits within one year (a target which is often missed in practice by the busier Local Divisions), the procedural framework forces parties to crystallise their FRAND narrative, evidence and economic analysis at a very early stage, leaving limited scope for late tactical adjustments.

Germany’s bifurcated system takes a different approach. Infringement and validity are decided in separate proceedings, which may give rise to an “injunction gap” that does not usually exist before the UPC. Although also front-loaded, German infringement proceedings are generally less strict on late filings. Hearing dates typically fall around 12 to 15 months after filing, depending on the venue, but can be scheduled even earlier. Germany is currently the quicker jurisdiction compared to the busy German Local Divisions of the UPC. However, this might change in the future as the distribution of cases across the UPC Local Divisions evens out.

Costs

Another practical differentiator is exposure to recoverable attorney costs. In both jurisdictions, the costs depend on the value in dispute. In German SEP proceedings, the value in dispute usually lies between € 500,000 and € 1.5 million; in the UPC, it tends to be higher due to its multi-territorial impact, e.g. € 2 to 3 million.

The UPC may expose a losing party to considerably higher costs than the German infringement pathway as shown in the following example (which excludes the fees and costs of validity proceedings which are to be expected in both jurisdictions):

German vs UPC infringement proceedings: cost comparison
German infringement proceedings
with a value in dispute of
€ 1.5 million
UPC infringement proceedings
with a value in dispute of
€ 3 million
Court fees
€ 25,014
€ 41,100*
Recoverable attorney costs
€ 43,197
Up to € 400,000

*(fixed + value-based fees)

Security for costs

Another material difference between German and UPC proceedings is the requirement to provide security for costs. In both proceedings, the claimant may be required to provide security at the defendant’s request. Under German law, in a few cases, claimants from certain countries may be obliged to provide security for costs. This depends on the ratification of certain international treaties. The amount must cover the defendant’s recoverable costs for the first instance and first appeal proceedings as well as the petition for leave to appeal to the German Federal Court (second appeal).

In German proceedings with a value in dispute of € 1.5 million, the security amount will be about € 150,000.

In UPC proceedings, the criteria for ordering security for costs are less clear-cut. According to the case law, the decisive factor is “whether the financial position of the Claimant gives rise to a legitimate and real concern that a possible order for costs may not be recoverable and/or the likelihood that a possible order for costs by the UPC may not, or in an unduly burdensome way, be enforceable” (see, for example, Munich Local Division, Order of 24 March 2026, case ref. UPC_CFI_617/2024 and UPC_CFI_398/2025, paragraph 15). This might be the case if there are doubts that the claimant has sufficient funds to reimburse the defendant or if the claimant is domiciled in a country in which enforcing the reimbursement might be “unduly burdensome”.

The amount of security ordered in UPC proceedings could be as high as the ceiling for the recoverable costs - in a case where the value in dispute is set to € 3 million this could result in a security of up to € 400,000.
‍
However, in the above-mentioned case, the UPC considered half of the ceiling amount sufficient. In addition, the claimant may be ordered to provide security for costs for the defendant’s counterclaim for revocation of the patent, which would double the required security for a UPC infringement case.

Enforcement Strategy

A first instance injunction before a German national court can only be enforced by providing an enforcement security. This security is necessary regardless of whether the court has ordered the claimant to provide security for costs. The amount of the security is intended to cover damages due to the defendant if the German court’s decision is reversed on appeal or the patent is invalidated.

In setting the enforcement security, German courts may use the value in dispute as an orientation point if they are not persuaded by the defendant’s arguments for a higher amount.

When it comes to enforcing UPC orders, it is at the discretion of the court whether the enforcement should be subject to the provision of an enforcement security. The court may refrain from ordering the provision of security – for example, if the claimant is domiciled in one of the contracting member states and has sufficient funds there.

If the UPC orders a security, it is likely that the amount will be higher than in German proceedings given the wider territorial scope of the relief and thus the claimant’s greater exposure to potential enforcement damages.

The claimant can decide to enforce only parts of the order thereby potentially reducing the amount of the required security. The claimant must notify the court which part(s) it intends to enforce and provide a certified translation of the order in the official language of a contracting member state in which the enforcement shall take place.

UPC - a potential rate-setting forum?

German courts have so far been reluctant to conduct a rate-setting – for example, the Munich and Frankfurt Regional Courts dismissed Samsung’s attempts in two recent cases. The exception is the 7th Chamber of the Munich Regional Court I, which calculated a FRAND rate for a cross-licence in ZTE v Samsung, without being asked by either party to do so. However, the parties in that case are not required to enter into a licence at the court-determined rate, and Germany is not expected to become a rate-setting jurisdiction.

In the UPC, a request for a FRAND rate determination in 2023 failed in the Mannheim Local Division. However, more recently, UPC judges in Mannheim and The Hague have indicated that they would consider conducting a FRAND rate determination. Thus, the UPC could emerge as a rate-setting forum in the future. Indications from the bench suggest that this would likely involve a dedicated, court-led hearing, lasting several days, supported by economic experts and decision-makers from both parties. The recent proceedings brought by Sun Patent Trust against Vivo before the Paris Local Division and Ericsson against Transsion before The Hague Local Division, in which – unlike previous cases – the claimant requested a FRAND determination are ones to watch.

If the UPC were to become an established rate-setting forum, this would be a major factor in the choice of UPC versus Germany – a SEP holder might embrace a rate-setting at the UPC or prefer to stick to the conduct-based assessment of the German courts.

Why are SEP owners returning to the UK to resolve their global FRAND disputes?

The perception in the last few years of the UK as an implementer-friendly jurisdiction is no longer valid.

  • The licence fees set by the UK courts have been substantial. The relatively low lump sum licence fees set by the first instance court in 2023 in InterDigital v Lenovo and Optis v Apple were increased on appeal – in the Optis case by an order of magnitude to US$502 million.
  • The impact of the controversial UK interim licence regime on SEP owners has been blunted after courts of other jurisdictions have taken measures (including “antiinterim licence injunctions”) to mitigate any perceived jurisdictional overreach. As a result, SEP owners are able to embrace or ignore a UK interim licence, and there have now been several cases in the UK in which the patent owner has embraced the court’s interim licence regime.
  • By entering into a UK interim licence, a SEP owner will receive a non-refundable payment, likely equal to the licensee’s latest counter-offer. That payment can be booked as revenue and used for any purpose, including to fund the UK litigation. In the recent case of TP-Link v Huawei, the non-refundable interim payment was US$12 million.

SEP owners are once again choosing the UK to resolve their global licensing disputes - recent examples include Huawei (in their dispute with TP-Link) and Nokia (against Warner Brothers and Paramount). There are a few reasons to expect more SEP owners will follow suit.

  1. A UK court‑determined global licence provides a route to recovering royalties on historic sales from the date of first infringement, together with interest. In Optis v Apple, the interest alone amounted to over US$200 million. Note, however, that this issue is currently the subject of an appeal to the UK Supreme Court.
  2. A UK rate-setting action is a way to force early disclosure of an implementer’s sales data which may help progress negotiations to a settlement.
  3. Injunctions are available in the UK – unless an implementer agrees to take a FRAND licence, the UK court will injunct them.
  4. The UK has moved away from a long multi-trial FRAND action; instead, proceedings typically move straight to a rate-setting trial, often expedited to occur within 12 months of the start of a UK action.

Conclusion

While SEP owners hope to avoid litigation, they must nevertheless plan for that eventuality. Infringement proceedings or court-led rate-setting or a combination of both are sometimes needed to kickstart a licensing program or unblock a stalemate in licensing negotiations, and litigation in Europe is an effective way of doing so, as well as a means for reaching a satisfying conclusion.

If you are an SEP owner and would like to design a European SEP litigation strategy that suits your portfolio and licensing goals, please contact us.

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​